Vir Biotechnology Inc 's Revenue in the fiscal year 2025 $ 68.56 millions
Vir Biotechnology Inc 's Revenue in the fiscal year 2024 $ 74.21 millions
Vir Biotechnology Inc 's Revenue in the fiscal year 2023 $ 86.18 millions
Vir Biotechnology Inc 's Revenue in the fiscal year 2022 $ 1,615.80 millions
Vir Biotechnology Inc 's Revenue in the fiscal year 2021 $ 1,095.42 millions
VIR Revenue second quarter 2026 Y/Y Growth Comment
Vir Biotechnology Inc achieved in the second quarter 2026, above Company average Revenue surge of 19647.6% year on year, to $ 238.95 millions.
Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 42 other companies have achieved higher Revenue growth. While Vir Biotechnology Inc ' s Revenue doubling of 19647.6% ranks overall at the positon no. 3180 in the second quarter 2026.
VIR Revenue ( Y/Y Growth %)
2026
2025
2024
2023
4th Quarter
December
-
417.95 %
-26.33 %
-66.02 %
3rd Quarter
September
-
-89.92 %
-9.85 %
-99.3 %
2nd Quarter
June
19647.6 %
-60.71 %
-18.95 %
-
1st Quarter
March
-
-94.63 %
-10.45 %
-94.89 %
FY
-
-7.63 %
-13.9 %
-
Financial Statements
Vir Biotechnology Inc 's second quarter 2026 Revenue
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Vir Biotechnology Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
0 %
0 %
0 %
VIR's II. Quarter Q/Q Revenue Comment
Improvement II. Quarter 2026where Vir Biotechnology Inc published Revenue of $ 238.95 millions should is starting point of positive performance.Vir Biotechnology Inc announced in the II. Quarter 2026 Revenue of $ 238.95 millions compare to recorded in previos quarter.
Within Biotechnology & Pharmaceuticals industry Vir Biotechnology Inc achieved highest sequential Revenue growth. While Vir Biotechnology Inc 's Revenue growth quarter on quarter, overall rank is .
Improvement II. Quarter 2026where Vir Biotechnology Inc published Revenue of $ 238.95 millions should is starting point of positive performance.Vir Biotechnology Inc announced in the II. Quarter 2026 Revenue of $ 238.95 millions compare to recorded in previos quarter.
Within Biotechnology & Pharmaceuticals industry Vir Biotechnology Inc achieved highest sequential Revenue growth. While Vir Biotechnology Inc 's Revenue growth quarter on quarter, overall rank is .
Vir Biotechnology Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 303.23
$ 65.49
$ 68.56
$ 16.86
$ 19.00
Y / Y Revenue Growth (TTM)
1495.93 %
213.96 %
-7.61 %
-78.55 %
-75.91 %
Year on Year Revenue Growth Overall
Ranking
# 3708
# 3501
# 2083
# 1482
# 2222
Seqeuential Revenue Change (TTM)
362.98 %
-4.46 %
306.62 %
-11.26 %
-8.92 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 3180
# 3017
# 1927
# 2205
# 1562
Cumulative Revenue growth Comment
Vir Biotechnology Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 1495.93% year on year, to $ 303 millions if the fiscal year would have ended in Jun 30 2026. Vir Biotechnology Inc 's trailing twelve months Revenue growth was higher than company's average 378.05% and higher than 213.96% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 362.98 % from $65.49 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at378.05%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 362.98 % increase from $65.49 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 521 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3501 to 3708.
Vir Biotechnology Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 1495.93% year on year, to $ 303 millions if the fiscal year would have ended in Jun 30 2026. Vir Biotechnology Inc 's trailing twelve months Revenue growth was higher than company's average 378.05% and higher than 213.96% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 362.98 % from $65.49 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at378.05%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 362.98 % increase from $65.49 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 521 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3501 to 3708.
About Vir Biotechnology Inc Revenue Growth Rates (VIR), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
27,694.64%